First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, login before proceeding.
How to access the Academy for the first time
Neurofibromatoses: New Frontiers in NF1, NF2, and Schwannomatosis
Monday, July 20, 2020
3:30 pm – 5:00 pm ET
www.acmgeducation.net
In this session, presenters will provide updates on new and major advances in the understanding and treatment of the neurofibromatoses (NF), including Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2) and schwannomatosis (SWN). The diagnostic criteria initially established by the NIH in 1987 (NF1, NF2) and 2005 (SWN) are currently being revised, and are expected to be published in the near future. Genetic testing has increased relevance due to some NF1 and NF2 genotype/phenotype correlations and the discovery of phenotypically similar conditions. New NF1 pediatric and adult practice resources published by ACMG, and include updated surveillance protocols and malignancy risk figures. Research and possible treatments for NF are also advancing.
Target Audience
All healthcare professionals interested in the diagnosis, management, treatment and prevention of genetic conditions and increasing their understanding of the genetic basis of common, chronic health problems affecting both children and adults will find the programming applicable to their practice.
Agenda
Learning Objectives
At the conclusion of this session, participants should be able to:
Moderator:
Heather B. Radtke, MS
Genetic counselor, Medical College of Wisconsin and Children's Tumor Foundation
Presenters
Bruce R. Korf, MD, PhD, FACMG
Chief Genomics Officer, University of Alabama Birmingham UAB
David Viskochil, MD, PhD, FACMG
Professor of Pediatrics, University of Utah
Ashley Cannon, PhD, MS
Assistant Professor, University of Alabama Birmingham UAB
David T. Miller, MD, PhD, FACMG
Associate Professor of Pediatrics, Harvard Medical School
Director of the Multidisciplinary Neurofibromatosis (NF) Clinic and NF Research Initiative (NFRI), Boston Children’s Hospital
Scott R. Plotkin, MD, PhD
Director, MGH/DFCI/BWH Neuro-Oncology Fellowship Program, Massachusetts General Hospital
Professor of Neurology, Harvard Medical School
Financial Disclosures
Disclosure Statement
It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Disclosure must include financial relationships of the individual and those of their spouse/partner. Individuals who do not disclose will be disqualified from participating in a CME activity.
This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity. ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.
NOTE:
Dr. Korf has disclosed that he is a consultant/advisory board for Genome Medical; and a consultant for AstraZeneca, SprinWorks Therapeutics.
Dr. Li has disclosed that he is a consultant/advisory board for Sanofi-Genzyme, Shire-Takeda; a consultant for Sanofi-Genzyme; and has external grant/research for Soleno Therapeutics, Shire-Takeda.
Has no relevant financial relationships to disclose.
Dr. Plotkin has disclosed that he is a consultant/advisory board for AstraZeneca; and has major stockholder/ownership interest in NFlection Therapeutics, NF2 Therapeutics.
Educational Credit
Accreditation Statement
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE (Continuing Education for non-physicians): This activity has been approved for CE credits.*The certificate is accepted by the ABMGG for certification.
Genetic Counselor Credit
The National Society of Genetic Counselors (NSGC) has authorized American College of Medical Genetics to offer up to 1.5 Category 1 contact hours for this activity. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.
ACMG will report completed accredited sessions to NSGC for credit certificates on December 4, 2020, December 3, 2021 and July 8, 2022. Submissions outside of these parameters may incur a processing fee of $35.
P.A.C.E.® CEUs- Laboratory Directors and Laboratory Personnel
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program. The American College of Medical Genetics and Genomics designates this OnDemand course for a maximum of 1.5 contact hours. ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider #50-11878. This course is registered # 20-775394 with CEBroker. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®
Claiming your Educational Credits
Complete the activity and carefully complete the evaluation form. Deadline to claim educational credits is within 30 days from the date of the webinar. ACMG will not accept any credit request for live meetings after that period.
HIPAA Compliance
The ACMG supports medical information privacy. While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the ACMG HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available on request.
Content Validation
ACMG follows the ACCME policy on Content Validation for CME activities, which requires:
Content Validation and Fair Balance
Off-label Uses of Products
When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.
Disclaimer
The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.